CA2343575A1 - Inhibition of smooth muscle cell migration by heme oxygenase 1 - Google Patents

Inhibition of smooth muscle cell migration by heme oxygenase 1 Download PDF

Info

Publication number
CA2343575A1
CA2343575A1 CA002343575A CA2343575A CA2343575A1 CA 2343575 A1 CA2343575 A1 CA 2343575A1 CA 002343575 A CA002343575 A CA 002343575A CA 2343575 A CA2343575 A CA 2343575A CA 2343575 A1 CA2343575 A1 CA 2343575A1
Authority
CA
Canada
Prior art keywords
heme oxygenase
smooth muscle
inhibition
cell migration
muscle cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002343575A
Other languages
French (fr)
Other versions
CA2343575C (en
Inventor
Gary J. Nabel
Elizabeth G. Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
The Regents Of The University Of Michigan
Gary J. Nabel
Elizabeth G. Nabel
Howard Hughes Medical Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan, Gary J. Nabel, Elizabeth G. Nabel, Howard Hughes Medical Institute filed Critical The Regents Of The University Of Michigan
Publication of CA2343575A1 publication Critical patent/CA2343575A1/en
Application granted granted Critical
Publication of CA2343575C publication Critical patent/CA2343575C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present method provides a method for inhibiting restenosis associated with mechanical injury of a blood vessel. Human heme oxygenase (I) (HO1) is directly administered at the site of injury. The present inventors have discovered that carbon monoxide generated by HO1 is involved in the molecular pathogenesis of vascular proliferative disorders. By using adenoviral-mediated expression of inducible heme oxygenase 1 in primary vascular smooth muscle cells (vsmc) in vivo, the present inventors demonstrate that in vivo expression of HO1 can be used to treat restenosis.
CA002343575A 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1 Expired - Fee Related CA2343575C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9770798P 1998-08-21 1998-08-21
US60/097,707 1998-08-21
PCT/US1999/019245 WO2000010613A2 (en) 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1

Publications (2)

Publication Number Publication Date
CA2343575A1 true CA2343575A1 (en) 2000-03-02
CA2343575C CA2343575C (en) 2008-08-05

Family

ID=22264750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002343575A Expired - Fee Related CA2343575C (en) 1998-08-21 1999-08-21 Inhibition of smooth muscle cell migration by heme oxygenase 1

Country Status (6)

Country Link
US (1) US6203991B1 (en)
EP (1) EP1109914B1 (en)
AU (1) AU5687799A (en)
CA (1) CA2343575C (en)
DE (1) DE69931376T2 (en)
WO (1) WO2000010613A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698531A (en) * 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US7238673B2 (en) * 1989-03-31 2007-07-03 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US8128963B2 (en) * 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7678390B2 (en) * 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
US7261881B1 (en) * 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US20020192688A1 (en) * 2001-04-05 2002-12-19 Xiaoming Yang Imaging nucleic acid delivery
AU2002256388A1 (en) * 2001-04-30 2002-11-11 Cell Genesys, Inc. Viral-mediated delivery and in vivo expression of polynucleotides encoding anti-angiogenic proteins
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
WO2002098432A1 (en) * 2001-06-01 2002-12-12 The Brigham And Women's Hospital, Inc. Methods of treating cardiac disorders
PT1404811E (en) * 2001-06-21 2009-01-22 Beth Israel Hospital Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis
US20030100889A1 (en) * 2001-07-05 2003-05-29 Nicolas Duverger Method of administration of a gene of interest to a vascular tissue
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CN1646140A (en) 2002-02-04 2005-07-27 阿尔法玛药品研发有限公司 Use of a compound having the ability to release CO in preparation of pharmaceutical compositions for treatment of inflammation
CN100393323C (en) * 2002-02-13 2008-06-11 贝思·伊斯雷尔·迪科尼斯医药中心 Methods of treating vascular disease
CA2482260A1 (en) 2002-04-15 2003-10-30 Beth Israel Deaconess Medical Center Inc. Use of heme oxygenase-1 and products of heme degradation
CN1652802A (en) * 2002-04-15 2005-08-10 联邦高等教育系统匹兹堡大学 Methods of treating necrotizing enterocolitis
CN100496509C (en) * 2002-04-15 2009-06-10 联邦高等教育系统匹兹堡大学 Carbon monoxide product and its uses for treating ileus
CA2485465A1 (en) * 2002-05-17 2003-11-27 Yale University Methods of treating hepatitis
EP1509237A4 (en) * 2002-06-05 2006-07-12 Univ Yale Methods of treating angiogenesis, tumor growth, and metastasis
MXPA04012863A (en) * 2002-06-21 2005-03-31 Univ Pittsburgh Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation.
AU2003283982A1 (en) * 2002-11-07 2004-06-03 University Of Pittsburgh Of The Commonwealth System Of High Education Treatment for hemorrhagic shock
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
ATE526038T1 (en) 2003-03-28 2011-10-15 Innovational Holdings Llc IMPLANTABLE MEDICAL DEVICE WITH CONTINUOUS MEDIUM CONCENTRATION DISTANCE
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
WO2006029046A2 (en) * 2004-09-03 2006-03-16 Yale University Use of leptin in wound healing
EP1790350A1 (en) * 2005-11-24 2007-05-30 Interstitial Therapeutics Use of keratinocyte composition for the treatment of restenosis
WO2007073226A1 (en) * 2005-12-20 2007-06-28 Alfama - Investigação E Desenvolvimento De Produtos Farmacêuticos Lda Method for treating a mammal by administration of a compound having the ability to release co
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
AU2008350903B2 (en) * 2008-02-19 2015-04-02 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066333A (en) 1994-09-22 2000-05-23 William Harvey Research Limited Pharmaceutical control of inflammation

Also Published As

Publication number Publication date
DE69931376T2 (en) 2007-04-19
US6203991B1 (en) 2001-03-20
EP1109914B1 (en) 2006-05-17
AU5687799A (en) 2000-03-14
EP1109914A2 (en) 2001-06-27
DE69931376D1 (en) 2006-06-22
WO2000010613A2 (en) 2000-03-02
WO2000010613A3 (en) 2000-07-06
CA2343575C (en) 2008-08-05

Similar Documents

Publication Publication Date Title
CA2343575A1 (en) Inhibition of smooth muscle cell migration by heme oxygenase 1
Sacerdoti et al. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats
Aiyar et al. Role of chromium (V), glutathione thiyl radical and hydroxyl radical intermediates in Chromium (VI)‐induced DNA Damage
ATE218164T1 (en) INHIBITION OF REPRODUCTION OF ARTERIAL SMOOTH MUSCLE CELLS
MXPA02007639A (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure.
ES2164841T3 (en) DERIVATIVES OF BENZOIMIDAZOL, ITS PREPARATION AND ITS THERAPEUTIC USES.
Matsushita et al. Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats
AU8647101A (en) Compounds having activity as inhibitors of cytochrome p450rai
Sivrikaya et al. The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle
Salvemini et al. Nitric oxide activates the cyclooxygenase pathway in inflammation
HK1046094A1 (en) Ppar delta inhibitors for the treatment of cardiovascular diseases
PL331104A1 (en) Therapeutic application of bam (cd40l) technology in treating diseases related to smooth muscles
NO20005223L (en) Composition and treatment of inflammatory bowel disease by administration of N-acetylglucosamine in the colon
Shen Inhibition of dihydropteridine reductase by catecholamines and related compounds
Keung A genuine organ specific alcohol dehydrogenase from hamster testes: Isolation, characterization and developmental changes
Kasemset et al. Regulation of Mn-SOD activity in the mouse heart: Glucose effect
JPS5645198A (en) Determination of amount of hydrogen peroxide of activity of peroxidase
JPS53148167A (en) Method of harmlessly burning waste gas and liquid
JPS53108838A (en) Austenitic stainless steel welded joint
WO2002085376A3 (en) A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
WO2003024394A3 (en) Method of treating benign prostatic hyperplasia and other beingn porstate conditions
JPS532435A (en) Preparation of phenols
Kinn et al. Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women.
PEEVA FROM THE PRACTICE OF ART THERAPY IN THE DAILY HOSPITAL FOR CHILDREN AND YOUTHS WITH ABNORMAL DEVELOP-MENT IN BLAGOEVGRAD
RU95113648A (en) METHOD FOR TREATING ENDOGENOUS INTOXICATION IN BURN DISEASE

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed